Lotte Bjerre Knudsen, who persuaded Novo Nordisk to stick with GLP-1 research an...
Monica Bertagnolli, the nominee to lead the NIH, spent her confirmation hearing ...
In drug development, large pharma companies’ staying power provides them an edge...
Investors in biopharma companies, who lobbied vigorously — but unsuccessfully — ...
Want to stay on top of the science and politics driving biotech today? Sign up t...
Biopharma investors, who lobbied against allowing Medicare to negotiate drug pri...
Not everyone loses weight on Ozempic-type drugs. Researchers are looking for gen...
There’s a specter haunting Wall Street: the Ozempic panic.
Hemsley, the former CEO of UnitedHealth Group and its current board chair, also ...
Preventive biologics can address the anti-infectives market failure while simult...
This week on the "First Opinion Podcast": an entirely new way to think about lon...
Waystar, a revenue cycle management company, filed for an IPO Monday.
Patient safety is paramount to the FDA, so stopping Cassava’s two Phase 3 studie...
Breast cancer is deadlier for Black women. A study of mammograms could help clos...
Doctors lowered the incidence of heart disease and strokes among their patients ...
